Prognostic implications of thick (≥4-mm) melanoma in the Era of intraoperative lymphatic mapping and sentinel lymphadenectomy

Annals of Surgical Oncology

Volumn 9, Issue 8, 2002, Pages 754-761

  Essner, Richard ^a   Chung, Mathew H ^a   Bleicher, Richard ^a   Hsueh, Eddy ^a   Wanek, Leslie ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Lymph node dissection; Malignant melanoma; Metastasis; Sentinel lymph node; Thick primaries

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PREDICTION; PROGNOSIS; SENTINEL LYMPH NODE; SKINFOLD THICKNESS; TUMOR VOLUME; ULCER;

ADULT; AGED; AGED, 80 AND OVER; COLORING AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; ROSANILINE DYES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0036789850     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2001.06.024     Document Type: Article

References (34)

1. Milton GW, Shaw HM, McCarthy WH, Pearson L, Balch CM, Soong SJ. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982,69:108-11.
2. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979;86: 343-51.
3. Rompel R, Garbe C, Buttner P, Teichelmann K, Petres J. Elective lymph node dissection in primary malignant melanoma: a matched-pair analysis. Melanoma Res 1995;5:189-94.
4. Slingluff CL, Stidham KR, Ricci WM, Stanley WE, Seigler HF. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg 1994;221: 120-30.
5. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: analysis of prognostic factors in 1134 patients from the John Wayne Cancer Institute. Ann Surg 1991; 214:491-501.
6. Sim FH, Taylor WF, Ivins JC, Pritchard DJ, Soule EH. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results. Cancer 1978;41:948-56.
7. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977;297:627-30.
8. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30.
9. Balch CM, Soong S-J, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-66.
10. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional lymph nodes in patients with melanoma of the trunk: a randomised trial. Lancet 1998;351:793-6.
11. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 1988;6:163-72.
12. Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-9.
13. Fee HJ, Robinson DS, Sample WF, Graham LS, Holmes EC, Morton DL. The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: a preliminary study. Surgery 1978;84:626-32.
14. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin in a sentinel lymph node in a feline model. Ann Surg 1991;214:637-41.
15. Reintgen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997; 225:1-14.
16. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma. A multicenter trial. Ann Surg 1999;230:453-65.
17. Shaw JHF, Rumball EM. Complications and local recurrence following lymphadenectomy. Br J Surg 1990;77:760-4.
18. Sahin S, Rao B, Kopf AW, et al. Predicting ten-year survival of patients with primary cutaneous melanoma. Corroboration of a prognostic model. Cancer 1997;80:1426-31.
19. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995;274:1703-5.
20. Schwimmer J, Essner R, Patel A, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000;44:153-67.
21. Essner R. The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Semin Oncol 1997;24: S4-8-10.
22. Essner R, Bostick PJ, Glass EC, et al. Standardized probe-directed sentinel node dissection in melanoma. Surgery 2000; 127:26-31.
23. Glass EC, Essner R, Morton DL. Kinetics of three lymphoscinti-graphic agents in patients with cutaneous melanoma. J Nucl Med 1998;39:1185-90.
24. Cochran AJ, Wen D-R, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma, Am J Surg Pathol 1988;12:612-8.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
26. Cox DR. Regression model and life tables. J R Stat Soc Br 1972;34:187-220.
27. Miliotes G, Albertini J, Berman C, et al. The tumor biology of melanoma nodal metastases. Am Surg 1996;62:81-8.
28. Thompson JF, McCarthy WH, Bosch CMJ, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255-60.
29. Leong SPL, Steinmetz I, Habib FA, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 1997;132:666-73.
30. Massi D, Borgognini L, Franchi A, Martini L, Reali UM, Santucci M, Thick cutaneous malignant melanoma: a reappraisal of prognostic factors. Melanoma Res 2000;10:153-64.
31. Kim SH, Garcia C, Rodriguez J, Coit DG, Prognosis of thick cutaneous melanoma. J Am Coll Surg 1999;188:241-7.
32. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma, Ann Surg Oncol 2000; 7:160-5.
33. Hoon DSB, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995;13:2109-16.
34. Essner R, Kuo CT, Wang H, et al. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer 1998;82:309-16.